enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Biogen Gains Momentum With Positive Lupus Drug Results ... - AOL

   www.aol.com/finance/biogen-gains-momentum...

   On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...

3. Biogen-UCB's lupus drug meets main goal of late-stage trial - AOL

   www.aol.com/news/biogen-ucbs-lupus-drug-meets...

   Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...

4. Litifilimab - Wikipedia

   en.wikipedia.org/wiki/Litifilimab

   Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti- BDCA2 monocolonal antibody. [ 1 ] [ 2 ] [ 3 ]

5. Roivant Sciences' lupus drug fails to reduce symptoms in mid ...

   www.aol.com/news/roivant-sciences-lupus-drug...

   The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...

6. Lupus anticoagulant - Wikipedia

   en.wikipedia.org/wiki/Lupus_anticoagulant

   A ratio of 1.2 is commonly used, such that a value <1.2 indicates the absence of a lupus anticoagulant, while a value >1.2 indicates the presence of a lupus anticoagulant. [19] Direct oral anticoagulants and vitamin K antagonists used to treat thrombosis can interfere with lupus anticoagulant assays and generate either false-positive or false ...

7. Obexelimab - Wikipedia

   en.wikipedia.org/wiki/Obexelimab

   Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells." [1] [2]

8. Dapirolizumab pegol - Wikipedia

   en.wikipedia.org/wiki/Dapirolizumab_pegol

   Dapirolizumab pegol is "a polyethylene glycol conjugated anti-CD40L Fab fragment" developed by Biogen for systemic lupus erythematosus. [ 1 ] [ 2 ] [ 3 ] References

9. AstraZeneca lupus drug shows promise after set-back last year

   www.aol.com/news/astrazeneca-lupus-drug-meets...

   The British drugmaker said anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final ...